ChiCTR2400094298 版本V1.0 版本创建时间2024/12/19 16:44:56 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2400094298 

最近更新日期:

Date of Last Refreshed on:

2024-12-19 16:44:44 

注册时间:

Date of Registration:

2024-12-19 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

探讨微量元素对WMT治疗自闭症患者临床疗效的影响

Public title:

To investigate the effect of trace elements on the clinical efficacy of WMT in the treatment of patients with autism

注册题目简写:

English Acronym:

研究课题的正式科学名称:

探讨微量元素对WMT治疗自闭症患者临床疗效的影响

Scientific title:

To investigate the effect of trace elements on the clinical efficacy of WMT in the treatment of patients with autism

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

卢盛华 

研究负责人:

何兴祥 

Applicant:

Lu Shenghua 

Study leader:

He Xingxiang  

申请注册联系人电话:

Applicant telephone:

+86 136 4033 2871

研究负责人电话:

Study leader's
telephone:

+86 137 2488 7928

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

564896266@qq.com

研究负责人电子邮件:

Study leader's E-mail:

13724887928@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

广州市越秀区农林下路19号

研究负责人通讯地址:

广州市越秀区农林下路19号

Applicant address:

No. 19, Nonglin Road, Yuexiu District, Guangzhou

Study leader's address:

No. 19, Nonglin Road, Yuexiu District, Guangzhou

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

广东药科大学附属第一医院

Applicant's institution:

The First Affiliated Hospital of Guangdong Pharmaceutical University

研究负责人所在单位:

广东药科大学附属第一医院

Affiliation of the Leader:

The First Affiliated Hospital of Guangdong Pharmaceutical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

医伦审[2024]IIT第(37)号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

广东药科大学附属第一医院伦理委员会

Name of the ethic committee:

Ethics Committee of the First Affiliated Hospital of Guangdong Pharmaceutical University

伦理委员会批准日期:

Date of approved by ethic committee:

2024-07-22 00:00:00

伦理委员会联系人:

詹振兴

Contact Name of the ethic committee:

Zhan Zhengxing

伦理委员会联系地址:

广州市越秀区竹丝岗二马路39-1中航大厦8005房

Contact Address of the ethic committee:

Room 8005, AVIC Building, 39-1 Zhusigang Erma Road, Yuexiu District, Guangzhou

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 20 8760 9616

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

广东药科大学附属第一医院

Primary sponsor:

The First Affiliated Hospital of Guangdong Pharmaceutical University

研究实施负责(组长)单位地址:

广州市越秀区农林下路19号

Primary sponsor's address:

No. 19, Nonglin Road, Yuexiu District, Guangzhou

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东

市(区县):

广州

Country:

China

Province:

Guangdong

City:

Guangzhou

单位(医院):

广东药科大学附属第一医院

具体地址:

广州市越秀区农林下路19号

Institution
hospital:

The first affiliated hospital of guangdong pharmaceutical university

Address:

No. 19, Nonglin Road, Yuexiu District, Guangzhou

经费或物资来源:

Source(s) of funding:

None

研究疾病:

自闭症  

Target disease:

Autism

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

评估微量元素对WMT治疗自闭症患者症状改善的影响  

Objectives of Study:

To assess the effect of micronutrients on symptom improvement in patients with autism treated with WMT

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

(1)年龄2-18周岁; (2)性别不限; (3)明确诊断为儿童自闭症患者,符合自闭症诊断访谈修订版(ADI-R)和DSM-5(精神障碍诊断与统计手册第五版;APA2013); (4)以前没有进行过洗涤菌群移植; (5)配合检查且签署知情同意书。

Inclusion criteria

(1) Age 2-18 years old; (2) Gender is not limited; (3) Patients with a definite diagnosis of childhood autism, in line with the Autism Diagnostic Interview Revised (ADI-R) and DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition; APA2013); (4) No previous transplantation of washing flora; (5) Cooperate with the examination and sign the informed consent form.

排除标准:

(1)在接受WMT治疗前1个月服用过抗生素或益生菌; (2)被诊断出患有炎症性肠病、消化道肿瘤、乳糜泻等需要紧急治疗的胃肠道疾病; (3)被诊断出患有严重的心脏、脑部、肺、肝或肾脏疾病。

Exclusion criteria:

(1) Have taken antibiotics or probiotics 1 month before receiving WMT treatment; (2) Diagnosed with inflammatory bowel disease, gastrointestinal tumors, celiac disease and other gastrointestinal diseases that require urgent treatment; (3) Diagnosed with severe heart, brain, lung, liver, or kidney disease.

研究实施时间:

Study execute time:

From 2024-12-31 00:00:00 To 2026-01-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-12-31 00:00:00 To 2026-01-01 00:00:00

干预措施:

Interventions:

组别:

自闭症患者组

样本量:

50

Group:

People with autism group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

广东 

市(区县):

广州 

Country:

China

Province:

Guangdong

City:

Guangzhou

单位(医院):

广东药科大学附属第一医院 

单位级别:

三甲 

Institution
hospital:

The First Affiliated Hospital of Guangdong Pharmaceutical University, No. 19, Nonglin Road, Yuexiu District, Guangzhou

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

微量元素6项

指标类型:

主要指标

Outcome:

6 trace elements

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

孤独症行为评定量表

指标类型:

主要指标

Outcome:

Autism Behavior Rating Scale

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

儿童孤独症评定量表

指标类型:

主要指标

Outcome:

Autism Rating Scale for Children

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

儿童睡眠紊乱量表

指标类型:

主要指标

Outcome:

Sleep Disturbance Scale for Children

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

布里斯托大便分类法

指标类型:

主要指标

Outcome:

Bristol Stool Scale

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

粪便

组织:

Sample Name:

Stool

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 2 years
最大 Max age 18 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

None

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

采用病历记录表收集和管理数据

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data collection and management are collected using medical record forms

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2024-12-19 16:44:44